Potomac Capital Management’s Gain Therapeutics GANX Stock Holding History
Bought
Maintained
Sold
Other funds holding GANX
Potomac Capital Management's GANX Position: Q3 2026 in Review
Potomac Capital Management reduced its Gain Therapeutics (GANX) stake by 1.7% in Q3 2026, selling an estimated $29.9K and leaving 930,000 shares worth $1.61M. The position accounts for 1.25% of the portfolio, ranked #23.
Potomac Capital Management first reported a position in GANX in Q4 2025 and has held it in 4 quarters since. The position peaked at $3.25M in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q3 2026.
- Potomac Capital Management held 930,000 shares of Gain Therapeutics worth $1.61M as of Q3 2026.
- Potomac Capital Management sold 16,400 Gain Therapeutics shares in Q3 2026, an estimated $29.9K.
- Gain Therapeutics made up 1.25% of Potomac Capital Management's portfolio in Q3 2026, its #23 holding.
- Potomac Capital Management first reported a position in Gain Therapeutics in Q4 2025 and has held it in 4 quarters since.
- Potomac Capital Management's Gain Therapeutics position peaked at $3.25M in Q4 2025.
- 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2026.
Based on Potomac Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.